Immunity to viruses: Learning from successful human vaccines

Immunological Reviews

Volumn 255, Issue 1, 2013, Pages 243-255

  Pulendran, Bali ^a,b   Oh, Jason Z ^a   Nakaya, Helder I ^a,b   Ravindran, Rajesh ^a   Kazmin, Dmitri A ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cells; Toll like receptors; Vaccination

Indexed keywords

ANTIGEN; B CELL MATURATION ANTIGEN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; INFLUENZA VACCINE; INITIATION FACTOR 2ALPHA; MYELOID DIFFERENTIATION FACTOR 88; NANOPARTICLE; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; PERK PROTEIN; PROTEIN KINASE; RANTES; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VIRUS VACCINE; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BLEEDING; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); COMMENSAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENDOPLASMIC RETICULUM STRESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA VIRUS A H5N1; INNATE IMMUNITY; INTESTINE FLORA; JAUNDICE; KIDNEY FAILURE; LONGEVITY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALAISE; MEDIATOR; MYALGIA; NONHUMAN; OLIGURIA; PARTICLE SIZE; PERSISTENT VIRUS INFECTION; PLASMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RESPIRATORY FAILURE; RNA VIRUS; SEASONAL INFLUENZA; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; UNFOLDED PROTEIN RESPONSE; VIROGENESIS; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS LOAD; VIRUS STRAIN; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

DENDRITIC CELLS; TOLL-LIKE RECEPTORS; VACCINATION;

ANIMALS; HUMANS; VIRAL VACCINES; VIRUS DISEASES; VIRUSES;

EID: 84881652428     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12099     Document Type: Article

References (116)

1. Querec TD, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009;10:116-125.
2. Gaucher D, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008;205:3119-3131.
3. Nakaya HI, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011;12:786-795.
4. Bucasas KL, et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011;203:921-929.
5. Furman D, et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol 2013;9:659.
6. Zak DE, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 2012;109:E3503-E3512.
7. Vahey MT, et al. Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS, S malaria vaccine. J Infect Dis 2010;201:580-589.
8. Obermoser G, et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013;38:831-844.
9. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009;9:741-747.
10. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity 2010;33:516-529.
11. Nakaya HI, Li S, Pulendran B. Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med 2012;4:193-205.
12. Li S, et al. Systems biological approaches to measure and understand vaccine immunity in humans. Semin Immunol 2013;doi: 10.1016/j.smim.2013.05.003.
13. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008;29:319-324.
14. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327:291-295.
15. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-384.
16. Wilkins C, Gale M Jr. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010;22:41-47.
17. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009;9:465-479.
18. Ting JP, Duncan JA, Lei Y. How the noninflammasome NLRs function in the innate immune system. Science 2010;327:286-290.
19. Querec T, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006;203:413-424.
20. Querec TD, Pulendran B. Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D. Adv Exp Med Biol 2007;590:43-53.
21. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011;12:509-517.
22. Barrett AD, Monath TP. Epidemiology and ecology of yellow fever virus. Adv Virus Res 2003;61:291-315.
23. Monath TP. Milestones in the conquest of yellow fever, in Microbe Hunters - Then and Now. Koprowski H, Oldstone MBA, eds. Bloomington: Medi-Ed Press, 1996: 456.
24. Theiler M, Smith HH. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med 1937;65:767-786.
25. Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937;65:787-800.
26. Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65, 787-800 (1937). Rev Med Virol 2000;10:6-16; discussion 3-5.
27. Santos AP, et al. Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. Cytokine 2008;42:152-155.
28. Sasaki S, et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007;81:215-228.
29. Gerin JL, Anderson NG. Purification of influenza virus in the K-II zonal centrifuge. Nature 1969;221:1255-1256.
30. Reimer C, et al. Purification of large quantities of influenza virus by density gradient centrifugation. J Virol 1967;1:1207-1216.
31. Luke CJ, Lakdawala SS, Subbarao K. Influenza vaccine-live. In: Vaccines. Plotkin SA, Orenstein W, Offit PA, eds. Philadelphia: Saunders, 2012: 294-311.
32. Wilkinson TM, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012;18:274-280.
33. Fiore AE, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1.
34. Sasaki S, et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 2008;3:e2975.
35. Smith DJ, et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004;305:371-376.
36. Zeman AM, et al. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 2007;26:107-115.
37. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol 2010;11:647-655.
38. Cao W, et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008;9:1157-1164.
39. Koyama S, et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2010;2:25ra24.
40. Geeraedts F, et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008;4:e1000138.
41. Koyama S, et al. Differential role of TLR-and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol 2007;179:4711-4720.
42. Poland J, et al. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981;59:895.
43. Hammarlund E, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003;9:1131-1137.
44. Mack TM, Noble J Jr, Thomas D. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972;21:214-218.
45. Crotty S, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003;171:4969-4973.
46. Bachmann MF, et al. Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med 1996;183:2259-2269.
47. McHeyzer-Williams M, et al. Molecular programming of B cell memory. Nat Rev Immunol 2012;12:24-34.
48. Bentebibel SE, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 2013;5:176ra32.
49. Sallusto F, et al. From vaccines to memory and back. Immunity 2010;33:451-463.
50. + cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr Opin Immunol 2001;13:479-482.
51. Callan M, et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-1402.
52. Hamann D, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997;186:1407-1418.
53. Lauer GM, et al. Comprehensive analysis of CD8+-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002;76:6104-6113.
54. Lechner F, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
55. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001;410:980-987.
56. Roos MTL, et al. Changes in the composition of circulating CD8+ T cell subsets during acute Epstein-Barr and human immunodeficiency virus infections in humans. J Infect Dis 2000;182:451-458.
57. Tan LC, et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-1835.
58. Urbani S, et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol 2002;76:12423-12434.
59. van Leeuwen EM, et al. Proliferation requirements of cytomegalovirus-specific, effector-type human CD8+ T cells. J Immunol 2002;169:5838-5843.
60. + T-cell memory using the yellow fever and smallpox vaccines. Immunol Cell Biol 2011;89:340-345.
61. Miller JD, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008;28:710-722.
62. Akondy RS, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009;183:7919-7930.
63. Meier KC, et al. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 2009;5:e1000614.
64. Belsher JL, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007;25:8480-8485.
65. Pulendran B, et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008;198:500-507.
66. Hinnebusch AG. Evidence for translational regulation of the activator of general amino acid control in yeast. Proc Natl Acad Sci USA 1984;81:6442-6446.
67. Sood R, et al. A mammalian homologue of GCN2 protein kinase important for translational control by phosphorylation of eukaryotic initiation factor-2α. Genetics 2000;154:787-801.
68. Lu J, et al. The interferon-induced double-stranded RNA-activated protein kinase PKR will phosphorylate serine, threonine, or tyrosine at residue 51 in eukaryotic initiation factor 2α. J Biol Chem 1999;274:32198-32203.
69. Anderson P, Kedersha N. Visibly stressed: the role of eIF2, TIA-1, and stress granules in protein translation. Cell Stress Chaperones 2002;7:213-221.
70. Proud CG. PKR: a new name and new roles. Trends Biochem Sci 1995;20:241-246.
71. Chen JJ, London IM. Regulation of protein synthesis by heme-regulated eIF-2 alpha kinase. Trends Biochem Sci 1995;20:105-108.
72. Chefalo PJ, et al. Inhibition of protein synthesis in insect cells by baculovirus-expressed heme-regulated eIF-2 alpha kinase. J Biol Chem 1994;269:25788-25794.
73. Chefalo PJ, et al. Heme-regulated eIF-2alpha kinase purifies as a hemoprotein. Eur J Biochem 1998;258:820-830.
74. Harding HP, et al. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 2000;5:897-904.
75. Harding HP, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003;11:619-633.
76. Dever TE. Gene-specific regulation by general translation factors. Cell 2002;108:545-556.
77. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol 2004;14:20-28.
78. Crosby JS, et al. Regulation of hemoglobin synthesis and proliferation of differentiating erythroid cells by heme-regulated eIF-2alpha kinase. Blood 2000;96:3241-3248.
79. Anthony TG, et al. Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2 kinase GCN2. J Biol Chem 2004;279:36553-36561.
80. Zhang P, et al. The GCN2 eIF2alpha kinase is required for adaptation to amino acid deprivation in mice. Mol Cell Biol 2002;22:6681-6688.
81. Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 2004;11:372-380.
82. Zhang P, et al. The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol Cell Biol 2002;22:3864-3874.
83. Lu B, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012;488:670-674.
84. Niwa M, Walter P. Pausing to decide. Proc Natl Acad Sci USA 2000;97:12396-12397.
85. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012;336:1268-1273.
86. Ichinohe T, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA 2011;108:5354-53559.
87. Hand TW, et al. Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses. Science 2012;337:1553-1556.
88. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-625.
89. Mazmanian SK, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122:107-118.
90. Abt MC, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 2012;37:158-170.
91. Naik S, et al. Compartmentalized control of skin immunity by resident commensals. Science 2012;337:1115-1119.
92. Ribar TJ, et al. Cerebellar defects in Ca2+/calmodulin kinase IV-deficient mice. J Neurosci 2000;20:RC107.
93. Wayman GA, et al. Analysis of CaM-kinase signaling in cells. Cell Calcium 2011;50:1-8.
94. Kitsos CM, et al. Calmodulin-dependent protein kinase IV regulates hematopoietic stem cell maintenance. J Biol Chem 2005;280:33101-33108.
95. Anderson KA, Means AR. Defective signaling in a subpopulation of CD4(+) T cells in the absence of Ca(2+)/calmodulin-dependent protein kinase IV. Mol Cell Biol 2002;22:23-29.
96. Chen R, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012;148:1293-1307.
97. Illario M, et al. Calmodulin-dependent kinase IV links Toll-like receptor 4 signaling with survival pathway of activated dendritic cells. Blood 2008;111:723-731.
98. Juang YT, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005;115:996-1005.
99. Schiemann B, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-2114.
100. Moore PA, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-263.
101. Vora KA, et al. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 2003;171:547-551.
102. Yan M, et al. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol 2000;1:37-41.
103. Rahman ZS, et al. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003;198:1157-1169.
104. Litinskiy MB, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-829.
105. Darce JR, et al. Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells. J Immunol 2007;178:5612-5622.
106. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008;8:663-674.
107. Sitia R, Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 2003;426:891-894.
108. Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest 2002;110:1383-1388.
109. Patil C, Walter P. Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. Curr Opin Cell Biol 2001;13:349-355.
110. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999;397:271-274.
111. Shi Y, et al. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol 1998;18:7499-7509.
112. Nakaya HI, Pulendran B. Systems vaccinology: its promise and challenge for HIV vaccine development. Curr Opin HIV AIDS 2012;7:24-31.
113. Shapira SD, Hacohen N. Systems biology approaches to dissect mammalian innate immunity. Curr Opin Immunol 2011;23:71-77.
114. Amit I, et al. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science 2009;326:257-263.
115. Root DE, et al. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 2006;3:715-719.
116. Amit I, Regev A, Hacohen N. Strategies to discover regulatory circuits of the mammalian immune system. Nat Rev Immunol 2011;11:873-880.